Pharmafile Logo

Understanding Patient Willingness to Pay

January 6, 2016 | emerging markets 

Published in eyeforpharma 12 October by Rachel Howard

What steps should pharma and medical device companies take to ensure they get their pricing strategy right in self-pay markets?

A key feature of emerging markets is that patients often have to self-fund a high proportion of their healthcare costs. For all but the most severe conditions, public reimbursement of pharmaceutical products and personal medical devices is often partial to non-existent, particularly in the outpatient setting. While private health insurance coverage is increasing in many emerging markets, penetration typically remains low, even among middle to high income segments of the population. This means that for many drugs and devices, the primary means of purchasing in emerging markets will be patients paying out of pocket. Any successful pricing strategy therefore needs to start with an understanding of target patients’ willingness to pay for the drug / device in question.

In this article, I partner with Research Partnership Quantitative Director and pricing expert Duncan Munro to set out the critical success factors that should be considered in order to determine how a medical product should be priced in a self-pay market.

Read the full article here:
www.researchpartnership.com/news/2015/10/article-understanding-patient-willingness-to-pay/


This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016

Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe. Living with UC is a quantitative study conducted online amongst 325 patients, including...

The Internet of Things

Evolution from man to machine

Therapy Watch expands its oncology portfolio

This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). Therapy Watch SCCHN is part of a wider portfolio...

Time for a new language for asthma?

Despite the global advances made in the treatment for asthma, many studies have shown that asthma remains uncontrolled for a large proportion of patients, when assessed according to international guidelines....

Evaluating the impact of your medical congress presence…more cost effectively

Organising a company’s presence, not just logistically, but in terms of delivering key information, data and messages, is a massive part of some people’s workload at this time of year....

Delivering multi-stakeholder patient journey insights in oncology with creative outputs and data visualisation

Two clients were co-developing a product and needed to understand the patient journey in two areas of oncology, in order to identify the leverage points where they could provide an...

Webinar: Understanding Patient Willingness to Pay

What steps should pharma and medical device companies take to ensure they get their pricing strategy right in self-pay markets?

Research Partnership welcomes 22 new Graduates

As part of our continued growth, we are delighted to announce a new intake of 17 Research Analysts and 5 Fieldwork Project Coordinators into our annual market research graduate programme.http://www.researchpartnership.com/news/2016/09/new-graduates-2016/

Case study: Tracking a product launch in a dynamic and competitive market

With the imminent expected approval and launch of a new product, our client needed to conduct global tracking research to understand knowledge, perceptions, awareness and recall around their product and the quality...

Understanding the Chronic Disease Patient Journey in Emerging Markets

The benefits of understanding the patient journey are well documented in mature markets. But in emerging markets the patient journey is less understood. We recently presented a webinar hosted by...